Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 13/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TACR3 | P29371 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5433090 | 0.93 | F10 (0.52) | F10ALDH1A1MAPTRECQLUSP2 | |
| SCHEMBL5429210 | 0.91 | F10 (0.51) | F10ALDH1A1MAPTRECQL | |
| SCHEMBL5438504 | 0.89 | ALDH1A1 (0.49) | F10ALDH1A1MAPTRECQLUSP2 | |
| SCHEMBL5431385 | 0.88 | F10 (0.55) | F10ALDH1A1MAPTSMN1; SMN2TACR3 | |
| SCHEMBL5428981 | 0.85 | F10 (0.49) | F10 | |
| SCHEMBL5432974 | 0.84 | F10 (0.50) | F10ALDH1A1MAPTRECQLUSP2 | |
| SCHEMBL5442070 | 0.83 | F10 (0.49) | F10ALDH1A1MAPTRECQLTACR3 | |
| SCHEMBL5438477 | 0.83 | F10 (0.60) | F10MAPTTACR3 | |
| SCHEMBL5428271 | 0.82 | F10 (0.56) | F10MAPTTACR3 | |
| SCHEMBL5428351 | 0.82 | F10 (0.59) | F10ALDH1A1MAPTSMN1; SMN2TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070129361-A1 | LACTAM-CONTAINING DIAMINOALKYL, Beta-AMINOACIDS, Alpha-AMINOACIDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | QIAO JENNIFER X | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129361-A1 | LACTAM-CONTAINING DIAMINOALKYL, Beta-AMINOACIDS, Alpha-AMINOACIDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | PEPD, XPNPEP1, METAP1 | F10 46/4885ALDH1A1 1204/4885MAPT 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.